INGREZZA patient cases in tardive dyskinesia
See results with INGREZZA from real-world and clinical trial patients
Review tardive dyskinesia (TD) movements across a broad range of adult patients and see the effect of treatment with INGREZZA® (valbenazine) capsules.
Real-world patient cases
Real-world cases feature patients treated with INGREZZA in clinical practice, and not from the INGREZZA clinical trial program. Treatment decisions were based on healthcare providers’ clinical judgement.

Debra
Major depressive disorder



INGREZZA treatment:
- INGREZZA 40 mg (Weeks 0–5) then INGREZZA 80 mg (Weeks 5–6)a
Medical history:
- Woman in her 50s living with severe major depressive disorder
- Previously treated with anticholinergic
Relevant treatment:
- Second-generation antipsychotics, which resulted in TD
Relevant concomitant treatment at baseline:
- Aripiprazole, quetiapine, escitalopram, buspirone, amantadine
TD history:
- Developed choreoathetoid movements 6 months prior to treatment with INGREZZA
- Presented with predominant trunk movements and abnormal movements of mouth and lips
Note: Not all movements may be visible in these videos
INGREZZA treatment results:
- At 6 weeks, HCP noted torso movements and overall body shaking were improved in intensity
- HCP notes patient did have some mouth and lip movements

Gloria
Schizoaffective disorder and depression





INGREZZA treatment:
- INGREZZA 40 mg (Week 1) then INGREZZA 80 mg (Weeks 2–6)a
Medical history:
- Woman in her 50s living with schizoaffective disorder and depression
- History of hospitalization, but circumstances were unknown
Relevant treatment:
- Second-generation antipsychotics, which resulted in TD
- Currently taking anticholinergic, but medical records were unavailable
Relevant concomitant treatment at baseline:
- Paliperidone palmitate 156 mg/QM, fluoxetine 40 mg/QD, benztropine 2 mg/BID
TD history:
- Presented with predominant jaw/mouth, hand, and foot movements
- Patient’s severe hand movement impacted self-feeding; she was also unable to communicate well due to tongue movements
Note: Not all movements may be visible in these videos
INGREZZA treatment results:
- At 2 weeks, symptoms showed improvement and HCP noted patient was more communicative
- Patient experienced somnolence
- At 4-week follow-up visit, HCP instructed patient to take INGREZZA HS
- At 6 weeks, patient’s family noted that movements were improved; HCP noted severe hand movements were reduced, enabling patient to self-feed
a | Patients were not a part of the INGREZZA clinical trials. Patients’ treating healthcare providers assessed for TD. Recordings were taken before initiation of INGREZZA and at follow-up after 6 weeks of treatment for Debra and after 2 and 6 weeks of treatment for Gloria. Treatment decisions were based on healthcare providers’ clinical judgment. These patients provided consent to allow Neurocrine Biosciences® to use their images/likeness and medical information. |
CONTACT A REPRESENTATIVE
Request an office visit from a Neurocrine representative to see more data and videos and to request INGREZZA samples and patient resources.
CONTACT A REPClinical trial videos
In KINECT 3, patients were randomized 1:1:1 to INGREZZA 40 mg, INGREZZA 80 mg, or placebo. Patients randomized to the 80 mg group received 40 mg for the first week.

Sue
Bipolar disorder





Clinical trial and treatment group:
- KINECT 3,b INGREZZA 80 mg
Relevant treatment:
- Second-generation antipsychotic to treat bipolar disorder, which resulted in TD
Relevant concomitant treatment at baseline:
- Ziprasidone 40 mg/QD, clonazepam 1 mg/QD, trazodone 150 mg/QD
Timing of TD diagnosis:
- Approximately 1 year prior to study enrollment
Affected body regions:
- Jaw, mouth, eyes (predominant), and hands
Note: Not all movements may be visible in these videos
INGREZZA treatment results:
- 6‑point reduction in AIMS score from baseline to Week 6; 7‑point reduction in AIMS score from baseline to Week 48 (Baseline = 10, Week 6 = 4, Week 48 = 3)
b |
KINECT 3 was a phase 3, multicenter, randomized, double-blind, placebo-controlled (DBPC), parallel, fixed‑dose study to evaluate the efficacy, safety, and tolerability of INGREZZA 40 mg and 80 mg, administered once daily, compared to placebo. If patients were unable to tolerate the 80 mg dose, the investigator could decrease the dose once at any time during the study. If they did not tolerate the new dose, then patients were discontinued from the study. The primary efficacy endpoint was mean change from baseline in Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score at Week 6 on INGREZZA 80 mg.1,2 |

Want to see more?
Access exclusive content
with INGREZZA Insider
Register now to access exclusive videos and case study content, plus stay up to date with the latest TD resources and information on INGREZZA.
REGISTER NOWREFERENCES:
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc
- Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484